Carbon Monoxide

Subscribe to Selected New Research on Carbon Monoxide

34476 relevant articles (1038 outcomes, 3549 trials/studies) found for this Bio-Agent

Description: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)

Also Known As:

Monoxide, Carbon; CO

Relationship Network

Bio-Agent Context: Research Results

Inorganic Chemicals: 5

Gases: 2792

Carbon Monoxide: 34476

Oxygen Compounds: 9

Oxides: 243

Carbon Monoxide: 34476

Inorganic Carbon Compounds

Carbon Monoxide: 34476

Experts

1.	Otterbein, Leo E: 17 articles (03/2007 - 01/2003)
2.	Choi, Augustine M K: 16 articles (10/2008 - 01/2003)
3.	Drake, Robert E: 16 articles (01/2008 - 10/2003)
4.	Nakao, Atsunori: 10 articles (10/2008 - 10/2003)
5.	Grant, Bridget F: 10 articles (07/2008 - 04/2004)
6.	Murase, Noriko: 9 articles (10/2008 - 10/2003)
7.	Pol, Stanislas: 8 articles (05/2008 - 05/2002)
8.	Brunette, Mary F: 8 articles (10/2007 - 10/2003)
9.	Kaprio, Jaakko: 7 articles (07/2008 - 09/2003)
10.	Benhamou, Yves: 7 articles (10/2006 - 01/2003)

Related Diseases

1.	Infection 06/01/2008 - "Although co-infection is the norm in most human and animal populations, clinicians currently have no practical tool to assist them in choosing the best treatment strategy for such patients" 11/01/2006 - "GLH resistant T(1) plants were further evaluated for the incidence of tungro disease, caused by co-infection of GLH vectored Rice tungro bacilliform virus (RTBV) and Rice tungro spherical virus (RTSV), which appeared to be dramatically reduced" 06/01/2006 - "In vivo priming protocols that preferentially induced one of the different CD8(+) T cell subsets demonstrated that predominance of T(EM) (CD40 stimulation) correlated best with effective protection against L.m., whereas generation of neither T(CM) (by immunization with heat-killed L.m.) nor T(EC) (by systemic co-administration of CpG during primary infection) conferred substantial long-term protective immunity" 03/01/2002 - "Infection was most effective when explants were infected with Agrobacterium for 15 min and co-cultivated for 2 days in the co-cultivation medium" 01/01/1996 - "In contrast, isolation of anti-HCV-positive dialysed patients does not appear to be warranted by prospective studies, as it might increase the risk of co-infection by different HCV strains, would entail additional costs and be at best partially effective" Order ALL the reference details at left...
2.	Neoplasms (Cancer) 04/25/2001 - "Tumor growth in the nude mice was dramatically reduced when normal ovarian surface stromal cells were co-injected with SKOV3 or OCC1 cells" 08/01/1995 - "Importantly, immunization of mice with the transfected cells and subsequent contralateral challenge with parental tumor cells showed that IL-7/B7 co-expressing cells induced the most strongly protective immunity, which is superior to that induced by single-gene transfectants and to the adjuvant Corynebacterium parvum" 12/01/1992 - "Co-injection of the two tumor cell classes resulted in similar numbers of homogeneous microfoci in lungs of LZEJ or APSI cells within minutes after injection that persisted for several hours before clearance of most of them" 05/15/1987 - "These results suggest that presentation of a hapten by highly immunogenic tumor cells can lead to enhanced protective immunity to poorly immunogenic noncross-reactive tumors that co-express the same hapten, and rejection of these haptenated poorly immunogenic tumors leads to enhanced protection against a subsequent challenge of the same, but not noncross-reactive progressor tumors." 03/01/1995 - "Considering that activated B cells express several kinds of costimulatory molecules, these findings thus indicate an efficacy of costimulation that is derived from activated B cells for the in vitro induction of tumor-specific CTL, in co-operation with anti-CD3 mAb. The culture system presented here may thus be therapeutically useful, providing potent effectors for adoptive immunotherapy against various types of cancer." Order ALL the reference details at left...
3.	Poisoning 01/01/2001 - "The most recent and best-designed randomized controlled clinical trial, performed in Salt Lake City, supports the efficacy of HBO2 in severe acute CO poisoning in accordance with scientific rationale and clinical experience" 07/01/2006 - "Further, it is generally believed that treatment of CO poisoning is more effective when performed as soon as possible after the exposure" 09/01/1996 - "CO detectors with audible alarms were effective in alerting the potential victims of CO poisoning to its presence" 01/01/1991 - "The present finding suggests that OHP is effective against the chronic state of the interval form of CO poisoning." 12/01/2006 - "In conclusion, the patterns in the basic activity change of EEG at the interval of 2 weeks in acute carbon monoxide intoxication are useful in monitoring efficacy of treatment." Order ALL the reference details at left...
4.	Weight Loss (Weight Reduction) 06/01/2005 - "The small number of side effects and complications, the excellent weight loss and the recovery of most co-morbidity leads to a great improvement in quality of life." 11/01/2007 - "All co-morbidities resolved completely with the weight loss" 01/01/2007 - "The mean weight loss was 28.5 +/- 19.6 kg, and clinical re-evaluation revealed significant improvement in patient co-morbidity status (mean 2.23 +/- .7, range 1-3; P = .024)" 01/01/2007 - "In the short-term 3-year follow-up, no statistically significant difference was registered between AGB and VBG in terms of weight loss, reduction of co-morbidities, or improvement in quality of life" 04/01/2006 - "CONCLUSION: RYGBP achieved significant durable weight loss and effectively treated co-morbid conditions in SO and SSO patients with acceptable postoperative morbidity and slightly greater mortality than in MO patients." Order ALL the reference details at left...
5.	Hypertension (High Blood Pressure) 02/01/2004 - "There was significant improvement in several co-morbid conditions, such as diabetes and hypertension" 11/01/1993 - "Co-presentation of hypertension and diabetes leads to a significantly greater increase of cardiovascular mortality than each disease separately" 10/01/2006 - "Patients have early satiety and major improvement in pre-surgical co-morbidities, especially diabetes and hypertension" 01/01/1975 - "The co-operation of patients in the management of the disease may be useful in the treatment of hypertension" 01/01/2005 - "The aim of this study was to compare the efficacy of a web-based computer-assisted education (CO-ED) system versus searching the Internet for learning about hypertension" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Carbon Monoxide
2.	Antigens
3.	Oxygen
4.	DNA (Deoxyribonucleic Acid)
5.	Ribavirin (Virazole)
6.	poly(lactide) (polylactide)
7.	Interferons
8.	Antibodies
9.	N-Methylaspartate (NMDA)
10.	Anti-Bacterial Agents (Antibiotics)

Related Therapies and Procedures

1.	Lasers (Laser)
2.	Drug Therapy (Chemotherapy)
3.	Transplants (Transplant)
4.	Gastric Bypass (Roux-en-Y Gastric Bypass)
5.	Bariatric Surgery

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 13871 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>